Mission
BetterLife’s mission is to deliver a better life, where individuals can live a full life without compromise. We are a life sciences company creating and clinically validating an evolving intellectual property portfolio of novel molecules and drug delivery mechanisms for development of products addressing mental health disorders.
TD-0148A
BetterLife intends to start a clinical trial utilizing TD-0148A in 2022 focused on: MDD / TRD (Major Depressive Disorder, or Treatment Resistant Depression, depending on jurisdiction.)
TD-010
BetterLife is at pre-clinical stage of development for the potential treatment of benzodiazepine dependency, anxiety and spasticity.
AP-003
BetterLife is planning clinical trials of AP-003 to test the efficacy of IFNa2b for treatment of COVID-19. AP-003 is being developed as a novel interferon alpha2b (IFNa2b) inhalation formulation.
IFNa2b has been used to treat COVID 19 in China.² Subject to receiving marketing authorization, AP-003 could potentially be used to treat patients early after COVID 19 infection which may potentially prevent the progression to severe disease and need for hospitalization.³
- Through its wholly-owned
subsidiary, Altum Pharmaceuticals Inc. - Dong et al, 2020; Lu, 2020; Shen & Yang, 2020; Zhou et al, 2020
- Altum Clin Protocol ALT 003 COV 01 2020 04 30
COVID-19 
Lymphoctyes 
Antibody 
Lung cells 
Cytokines